Senores Pharmaceuticals Q2 FY27 Results Due October 29

Board meeting scheduled for October 29

Senores Pharmaceuticals is scheduled to report its unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026. The company’s board is meeting on Thursday, October 29, 2026, to consider and approve the financial statements. The September quarter is the second quarter of FY27, covering July to September 2026. As of the stated schedule, the results were due on October 29 and were not yet available on the NSE results page referenced in the source material. The filing will provide the first reported view of the company’s performance for the July-September period. It will also include half-year figures for the six months ended September 30. Investors will be able to assess both consolidated and standalone numbers once the board-approved results are released.

Q2 results will cover September quarter performance

The board meeting intimation issued on October 22 said the agenda included unaudited consolidated and standalone financial results for the September 2026 quarter and half year. Consolidated results include the financial performance of the group, while standalone results relate to the company’s own operations. The company has not provided Q2 FY27 sales, profit, margin, or earnings-per-share figures in the information supplied. Therefore, any assessment of the September quarter’s financial outcome must wait for the official release. The announcement date falls 29 days after the September 30 quarter-end, according to the results-date information. That timetable is listed as Q2 FY27 for the July-September 2026 period. The market’s immediate focus will be on the figures released by the company rather than expectations not stated in its filings.

June quarter provides the latest reported comparison

The most recent reported consolidated quarterly data is for June 2026, the first quarter of FY27. Consolidated sales were reported at ₹180 crore, compared with ₹138 crore in June 2025, representing year-on-year growth of 31%. EBITDA rose 57% year on year to ₹54 crore from ₹34 crore. Net profit increased 44% to ₹30 crore from ₹21 crore. Earnings per share rose to ₹6.61 from ₹4.60 in the year-earlier quarter. Compared with March 2026, sales increased from ₹175 crore to ₹180 crore, while EBITDA rose from ₹47 crore to ₹54 crore. Net profit was lower than the ₹37 crore reported in March 2026, and EPS declined from ₹7.96.

June FY27 consolidated financial snapshot

The figures above are consolidated and are drawn from Senores Pharmaceuticals’ exchange filings as cited in the supplied material. Year-on-year comparisons use the April-June 2025 quarter as the base. EBITDA is described in the source as revenue from operations less operating costs, before other income. A separate report said consolidated June-quarter net sales were ₹180.21 crore, up 30.6% year on year. It also reported June-quarter revenue of ₹183.02 crore, up 24.69% from ₹146.78 crore a year earlier, and net profit of ₹30.45 crore versus ₹21.18 crore. These more precise figures are consistent in direction with the rounded quarterly table.

March quarter set a higher sequential profit base

For the March 2026 quarter, Senores Pharma reported consolidated net sales of ₹175.19 crore, up 53.39% year on year. The source also reported standalone March-quarter net sales of ₹36.81 crore, an increase of 210.37% year on year. In the rounded consolidated table, March-quarter EBITDA stood at ₹47 crore and net profit at ₹37 crore. The June 2026 quarter therefore showed stronger sales and EBITDA than the preceding March quarter, but a lower reported net profit. This makes the upcoming Q2 release relevant for tracking whether the June-quarter trend continued through the September period. The results will show the company’s reported performance across the first half of FY27. No Q2 comparison figures have been provided before the board meeting.

Earnings call time revised to 4 PM

Senores Pharmaceuticals has scheduled an earnings conference call following the Q2 FY27 results announcement. The company originally announced the call for 5:00 PM IST on October 29. A Regulation 30 disclosure dated October 23 stated that the call had been rescheduled to 4:00 PM IST on the same day. Management is expected to discuss the financial performance and respond to investor queries, according to the announcement. The company said dial-in details would be available for participants worldwide. The call follows the release of unaudited Q2 results and is intended for shareholders and other market participants. The revised 4:00 PM IST timing is the latest schedule cited in the supplied disclosures.

Operating-profit series shows a separate reported measure

The supplied historical table lists operating profit and operating profit margin across quarterly periods from December 2023 through June 2026. It shows operating profit of negative ₹2.33 crore and an operating profit margin of negative 8.63% for June 2026. The same table records negative ₹3.48 crore and negative 9.45% for March 2026. It also notes that earnings include other income of ₹56.5 crore. The source does not provide sufficient detail to reconcile this operating-profit series with the consolidated EBITDA and net-profit data. As a result, the measures should not be treated as directly comparable without the company’s detailed financial statements. The upcoming filing may offer additional context through its reported profit-and-loss statements and notes.

What investors can track in the release

The Q2 filing will provide reported consolidated and standalone sales, profitability, and earnings data for the September quarter. It will also allow a comparison with the June 2026 quarter and the September 2025 period, subject to the figures disclosed by the company. Half-year results will add a view of performance over the April-September 2026 period. The management call may provide commentary on the published financial statements and respond to questions from participants. However, no future guidance, operational update, or Q2 financial estimate has been stated in the information provided. Investors should distinguish between the officially released results and figures from earlier quarters. The October 29 board outcome and the 4:00 PM IST conference call are the next confirmed events in the company’s FY27 results calendar.

Conclusion

Senores Pharmaceuticals is due to place its Q2 FY27 and first-half FY27 unaudited results before its board on October 29, 2026. The latest available consolidated data showed June-quarter sales of ₹180 crore, EBITDA of ₹54 crore, and net profit of ₹30 crore. The company will hold its Q2 earnings call at 4:00 PM IST after the results release. The official filing will determine the reported September-quarter financial performance and provide the basis for investor assessment.